Regulatory and legal status

Read this first

United States

Under 21 U.S.C. § 813[1], a non-scheduled compound that is structurally and/or pharmacologically substantially similar to a Schedule I or II substance can be treated as a Schedule I substance for criminal prosecution if it is intended for human consumption. Importation, distribution, or possession-for-human-use of SR-17018 carries meaningful federal legal exposure.

State laws. Several U.S. states have analog laws or designer-drug provisions that may apply independently of federal action.

Germany / U.K. / E.U.

• Germany: Controlled under the Neue-psychoaktive-Stoffe-Gesetz (NpSG) since late 2025[2].
• United Kingdom: Likely captured under the Psychoactive Substances Act 2016[3], which criminalizes production, supply, and import of psychoactive substances regardless of specific scheduling.
• European Union: No EU-wide scheduling of SR-17018 specifically. EMCDDA monitoring of orphine-class novel psychoactive substances is ongoing[4].

Elsewhere

• Russia, Belarus: Not controlled as of 2023.
• Australia, Canada, Japan: No specific scheduling identified at time of writing; analogue and generic provisions may apply.

What this means for vendors

SR-17018 is widely sold by international research-chemical vendors with disclaimers indicating it is "not for human consumption." Quality control, identity verification, and purity in this market are unregulated. The "not for human consumption" disclaimer is a legal posture, not a statement of how customers actually use the material — and under U.S. analogue-statute case law, the seller's intent is one of several factors that determine whether the disclaimer offers meaningful protection.